Morgan Stanley
CBIO

Morgan Stanley’s Crescent Biopharma CBIO Stock Holding History

Morgan Stanley’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
17,698
-879
-5% -$17.2K ﹤0.01% 5754
2026
Q1 		$341K Sell
18,577
-8,944
-32% -$103K ﹤0.01% 5656
2025
Q4 		$326K Buy
27,521
+27,376
+18,880% +$349K ﹤0.01% 5723
2025
Q3 		$1.72K Sell
145
-15,249
-99% -$202K ﹤0.01% 7331
2025
Q2 		$248K Buy
15,394
+15,342
+29,504% +$325K ﹤0.01% 5767
2025
Q1 		$1.09K Hold
52
– – ﹤0.01% 7271
2024
Q4 		$1.29K Hold
52
– – ﹤0.01% 7242
2024
Q3 		$874 Hold
52
– – ﹤0.01% 7240
2024
Q2 		$1.46K Sell
52
-979
-95% -$102K ﹤0.01% 7110
2024
Q1 		$309K Buy
1,031
+341
+49% +$102K ﹤0.01% 5539
2023
Q4 		$163K Buy
690
+286
+71% +$44.5K ﹤0.01% 6023
2023
Q3 		$60.6K Sell
404
-575
-59% -$90.7K ﹤0.01% 6085
2023
Q2 		$170K Sell
979
-689
-41% -$116K ﹤0.01% 5712
2023
Q1 		$210K Buy
1,668
+1,505
+923% +$339K ﹤0.01% 5688
2022
Q4 		$49.5K Sell
163
-273
-63% -$40.2K ﹤0.01% 6298
2022
Q3 		$24K Hold
436
– – ﹤0.01% 6712
2022
Q2 		$26K Sell
436
-1
-0.2% -$74 ﹤0.01% 6883
2022
Q1 		$50K Sell
437
-95
-18% -$11.1K ﹤0.01% 6703
2021
Q4 		$76K Sell
532
-147
-22% -$26.7K ﹤0.01% 6590
2021
Q3 		$148K Buy
679
+235
+53% +$49.8K ﹤0.01% 6153
2021
Q2 		$103K Sell
444
-1,559
-78% -$397K ﹤0.01% 6347
2021
Q1 		$603K Sell
2,003
-3,465
-63% -$1.24M ﹤0.01% 5048
2020
Q4 		$2.06M Buy
5,468
+2,415
+79% +$846K ﹤0.01% 4133
2020
Q3 		$937K Sell
3,053
-3,576
-54% -$1.37M ﹤0.01% 4253
2020
Q2 		$2.49M Buy
6,629
+1,829
+38% +$518K ﹤0.01% 3379
2020
Q1 		$1.09M Buy
4,800
+2,067
+76% +$790K ﹤0.01% 3881
2019
Q4 		$1.45M Buy
2,733
+2,638
+2,777% +$1.43M ﹤0.01% 4275
2019
Q3 		$40K Buy
95
+81
+579% +$52.1K ﹤0.01% 5806
2019
Q2 		$16K Sell
14
-52
-79% -$62.2K ﹤0.01% 6001
2019
Q1 		$83K Sell
66
-470
-88% -$538K ﹤0.01% 5475
2018
Q4 		$507K Sell
536
-35
-6% -$42.1K ﹤0.01% 4773
2018
Q3 		$822K Sell
571
-158
-22% -$239K ﹤0.01% 4683
2018
Q2 		$1.18M Buy
729
+618
+557% +$1.06M ﹤0.01% 4506
2018
Q1 		$179K Buy
111
+77
+226% +$160K ﹤0.01% 5513
2017
Q4 		$57K Buy
34
+33
+3,300% +$43.6K ﹤0.01% 5794
2017
Q3 		$1K Sell
1
-75
-99% -$88K ﹤0.01% 6443
2017
Q2 		$85K Sell
76
-81
-52% -$66.9K ﹤0.01% 5693
2017
Q1 		$85K Sell
157
-194
-55% -$119K ﹤0.01% 5654
2016
Q4 		$214K Buy
351
+329
+1,495% +$205K ﹤0.01% 5327
2016
Q3 		$16K Buy
22
+17
+340% +$13K ﹤0.01% 5977
2016
Q2 		$3K Sell
5
-18
-78% -$12.4K ﹤0.01% 6298
2016
Q1 		$14K Sell
23
-32
-58% -$16.4K ﹤0.01% 6033
2015
Q4 		$32K Sell
55
-50
-48% -$33.1K ﹤0.01% 5876
2015
Q3 		$59K Sell
105
-15
-13% -$10.8K ﹤0.01% 5665
2015
Q2 		$96K Hold
120
– – ﹤0.01% 5608
2015
Q1 		$100K Buy
+120
New +$93.2K ﹤0.01% 5525
2014
Q3 		– Sell
-66
Closed -$56K – 6597
2014
Q2 		$56K Sell
66
-237
-78% -$236K ﹤0.01% 5730
2014
Q1 		$495K Buy
+303
New +$367K ﹤0.01% 4565

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM

Morgan Stanley's CBIO Position: Q2 2026 in Review

Morgan Stanley reduced its Crescent Biopharma (CBIO) stake by 4.7% in Q2 2026, selling an estimated $17.2K and leaving 17,698 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #5754.

Morgan Stanley first reported a position in CBIO in Q1 2014 and has held it in 48 quarters since. The position peaked at $2.49M in Q2 2020. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Morgan Stanley held 17,698 shares of Crescent Biopharma worth $319K as of Q2 2026.
  • Morgan Stanley sold 879 Crescent Biopharma shares in Q2 2026, an estimated $17.2K.
  • Crescent Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5754 holding.
  • Morgan Stanley first reported a position in Crescent Biopharma in Q1 2014 and has held it in 48 quarters since.
  • Morgan Stanley's Crescent Biopharma position peaked at $2.49M in Q2 2020.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.